[MS11-4C-3] Ketogenic diet effects on the clinical features of children with pharmacoresistant epileptic encephalopathy: A prospective study
[Objective]: This study aimed to determine the impact of a ketogenic diet (KD) on pharmacoresistant epileptic encephalopathy.
[Methods]:The data of 52 epileptic encephalopathy patients receiving treatment of KD from July 2012 to Jun 2015 in Department of Pediatric Neurology in Shengjing Hospital of China Medical University were analyzed retrospectively. Modified Johns Hopkins protocol was used to initiate KD，and urinary ketone bodies were daily monitored in the patients to maintain the state of ketosis. The effect was evaluated by Engel outcome scale. The EEG，cognition，language，and motor function of the patients were assessed.
[Results]: Totally 52 patients received treatment of KD more than 12 weeks. 14 patients were seizure free. After 12 weeks of treatment with KD，52 patients achieved Ⅰ，Ⅱ，Ⅲ，Ⅳ grade effect，accounting for 26.9%、17.3%、11.5%、44.2%, respectively according to Engel scale. KD is particularly effective in myoclonic astatic epilepsy(MAE；Doose Syndrome)and West syndrome with 100％and 57.9％ of the patients having a greater than 50％ seizure reduction,respectively．After KD treatment，the background rhythm of EEG showed obvious improvement in 19 patients. Cognitive function of 23 patients was improved. Language was enhanced in 12 patients. Motor function was improved in 10 patients.
[Conclusions]: The KD is safe and effective in treating children with pharmacoresistant epileptic encephalopathy.
[Methods]:The data of 52 epileptic encephalopathy patients receiving treatment of KD from July 2012 to Jun 2015 in Department of Pediatric Neurology in Shengjing Hospital of China Medical University were analyzed retrospectively. Modified Johns Hopkins protocol was used to initiate KD，and urinary ketone bodies were daily monitored in the patients to maintain the state of ketosis. The effect was evaluated by Engel outcome scale. The EEG，cognition，language，and motor function of the patients were assessed.
[Results]: Totally 52 patients received treatment of KD more than 12 weeks. 14 patients were seizure free. After 12 weeks of treatment with KD，52 patients achieved Ⅰ，Ⅱ，Ⅲ，Ⅳ grade effect，accounting for 26.9%、17.3%、11.5%、44.2%, respectively according to Engel scale. KD is particularly effective in myoclonic astatic epilepsy(MAE；Doose Syndrome)and West syndrome with 100％and 57.9％ of the patients having a greater than 50％ seizure reduction,respectively．After KD treatment，the background rhythm of EEG showed obvious improvement in 19 patients. Cognitive function of 23 patients was improved. Language was enhanced in 12 patients. Motor function was improved in 10 patients.
[Conclusions]: The KD is safe and effective in treating children with pharmacoresistant epileptic encephalopathy.